Abstract：
BACKGROUND: The pituitary tumor-transforming gene 1 (PTTG1), also recognized as securin, plays a crucial role in diverse biological processes, such as restraining sister chromatid segregation, facilitating DNA repair, contributing to organ development, and governing angiogenesis. Additionally, it regulates the expression and secretion of transfer factors. The epigenetic characteristics of PTTG1 suggest its potential in elucidating the progression of malignant tumors in pan-cancer. Nevertheless, the current comprehension of this relationship remains limited, necessitating further comprehensive studies to delve into the underlying pathogenesis.
METHODS: This investigation aimed to explore the potential functions of PTTG1 in pan-cancer by leveraging existing databases, such as TCGA and GTEx. Notably, PTTG1 was overexpressed in nearly all tumors, indicating promising prognostic and diagnostic capabilities. Moreover, the observed correlation between PTTG1 and immune cell infiltration, immune checkpoint genes, tumor mutational burden (TMB), microsatellite instability (MSI), and other immune features suggests its potential utility as a guide for immunotherapy.
RESULTS: The study unveils that the downregulation of PTTG1 expression in neuroblastoma results in reduced cell proliferation and increased apoptosis, substantiating the proposition that PTTG1 could serve as both a prognostic biomarker and a potential target for immunotherapy across various cancer types.
CONCLUSIONS: This study centers on the exploration of the expression and role of PTTG1 in both tumors and the tumor microenvironment (TME), offering valuable insights for the development of cancer therapeutic strategies. These discoveries present potential alternative avenues for addressing clinically resistant cancers.
METHODS: This investigation aimed to explore the potential functions of PTTG1 in pan-cancer by leveraging existing databases, such as TCGA and GTEx. Notably, PTTG1 was overexpressed in nearly all tumors, indicating promising prognostic and diagnostic capabilities. Moreover, the observed correlation between PTTG1 and immune cell infiltration, immune checkpoint genes, tumor mutational burden (TMB), microsatellite instability (MSI), and other immune features suggests its potential utility as a guide for immunotherapy.
RESULTS: The study unveils that the downregulation of PTTG1 expression in neuroblastoma results in reduced cell proliferation and increased apoptosis, substantiating the proposition that PTTG1 could serve as both a prognostic biomarker and a potential target for immunotherapy across various cancer types.
CONCLUSIONS: This study centers on the exploration of the expression and role of PTTG1 in both tumors and the tumor microenvironment (TME), offering valuable insights for the development of cancer therapeutic strategies. These discoveries present potential alternative avenues for addressing clinically resistant cancers.
摘要：
背景：垂体肿瘤转化基因1（PTTG1），也被认为是securin，在各种生物过程中起着至关重要的作用，例如限制姐妹染色单体分离，促进DNA修复，促进器官发育，和控制血管生成。此外,它调节转移因子的表达和分泌。PTTG1的表观遗传特征表明其在阐明泛癌症中恶性肿瘤的进展方面的潜力。然而，目前对这种关系的理解仍然有限，需要进一步的全面研究来深入研究潜在的发病机制。
方法：这项研究旨在通过利用现有数据库探索PTTG1在泛癌症中的潜在功能，例如TCGA和GTEx。值得注意的是,PTTG1在几乎所有肿瘤中过表达，表明有希望的预后和诊断能力。此外，观察到PTTG1与免疫细胞浸润之间的相关性，免疫检查点基因，肿瘤突变负荷（TMB），微卫星不稳定性（MSI），和其他免疫功能表明其作为免疫疗法指南的潜在效用。
结果：该研究揭示了神经母细胞瘤中PTTG1表达的下调导致细胞增殖减少和凋亡增加，这证实了PTTG1既可以作为预后生物标志物，也可以作为各种癌症类型的免疫疗法的潜在靶标。
结论：本研究集中于探索PTTG1在肿瘤和肿瘤微环境（TME）中的表达和作用。为癌症治疗策略的发展提供有价值的见解。这些发现为解决临床耐药性癌症提供了潜在的替代途径。
方法：这项研究旨在通过利用现有数据库探索PTTG1在泛癌症中的潜在功能，例如TCGA和GTEx。值得注意的是,PTTG1在几乎所有肿瘤中过表达，表明有希望的预后和诊断能力。此外，观察到PTTG1与免疫细胞浸润之间的相关性，免疫检查点基因，肿瘤突变负荷（TMB），微卫星不稳定性（MSI），和其他免疫功能表明其作为免疫疗法指南的潜在效用。
结果：该研究揭示了神经母细胞瘤中PTTG1表达的下调导致细胞增殖减少和凋亡增加，这证实了PTTG1既可以作为预后生物标志物，也可以作为各种癌症类型的免疫疗法的潜在靶标。
结论：本研究集中于探索PTTG1在肿瘤和肿瘤微环境（TME）中的表达和作用。为癌症治疗策略的发展提供有价值的见解。这些发现为解决临床耐药性癌症提供了潜在的替代途径。
